Sandoz Canada, Inc.

Sandoz Canada expands portfolio launching Enzeevu ® , company's first ophthalmology biosimilar Enzeevu ® is approved for all indications of reference medicine EYLEA ® 1 , including neovascular age-related macular degeneration and diabetic macular edema Launch supports improved affordability and access to retinal disease treatments across Canada SAINT-HUBERT, QC , Feb. 2, 2026 /CNW/ - Sandoz, the global leader in affordable medicines, today announced the launch of Enzeevu ® (aflibercept) in Canada, its first ophthalmology biosimilar, expanding access to affordable treatment options for people living with serious retinal diseases across Canada. Enzeevu ® is a biosimilar to the reference medicine EYLEA ® and is approved for all indications of the reference medicine: neovascular (wet) age-related macular degeneration (AMD) visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) diabetic macular edema (DME) myopic choroidal neovascularization (myopic CNV) These conditions are among the leading causes of vision impairment in Canada, particularly affecting older adults and people living with diabetes. 2 "With the growing prevalence of retinal diseases, access to effective and affordable treatment options has never been more important," said Michel Robidoux , President and General Manager of Sandoz Canada. "By offering a biosimilar to one of the most widely used therapies in this field, we are helping to improve affordability and access for thousands of patients nationwide." Enzeevu ® is supplied as a 2 mg/0.05 mL solution for intravitreal injection in a single-use pre-filled syringe, delivering a single dose of 2 mg aflibercept. The product has a similar appearance to the reference medicine, supporting continuity of care and facilitating the transition for patients currently receiving treatment. Patients and healthcare professionals will also benefit from a comprehensive patient support program during treatment with Enzeevu ® , providing practical support and guidance throughout the entire patient experience. This launch reinforces the Sandoz Purpose of pioneering access for patients and reflects the company's continued commitment to expanding its biosimilars portfolio into new therapeutic areas, including ophthalmology. As a leader in affordable medicines, Sandoz Canada continues to work with healthcare partners to support sustainable healthcare systems and improved patient outcomes. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. ABOUT SANDOZ CANDA As a Canadian leader in off-patent medicines, Sandoz Canada has a product portfolio that includes over 700 generics and biosimilars spanning multiple therapeutic areas, such as anti-infective, cardiovascular, central nervous system, immunology and oncology. In 2025, 59 million Sandoz prescriptions were issued in Canada (source: IQVIA Compuscript TRx, MAT 2025). Sandoz Canada employs 300 people across the country and at its head office in Saint-Hubert, Quebec. It is a trusted partner for pharmacists, physicians and hospitals for quality medicine and outstanding customer service and is committed to ensuring a reliable supply. For more information about Sandoz Canada, visit . REFERENCES 1 EYLEA ® is a registered trademark of Bayer Inc. 2 Fighting Blindness in Canada. A Report Card on Vision Health in Canada 2023 . SOURCE Sandoz Canada

PrSandoz® Edoxaban is approved for all indications of reference medicine PrLixiana® including preventing thromboembolic complications from atrial fibrillation or venous thromboembolism Available in 15 mg, 30 mg and 60 mg tablets, Edoxaban has a similar appearance to the reference medicine to facilitate patients’ transition This launch is expected to generate savings for governments, private insurers and patients Boucherville, Quebec, May 6, 2025 – Sandoz Canada, a leader in generics and biosimilars, announces today the launch of PrSandoz® Edoxaban, a generic equivalent of PrLixianaTM. The product is approved for all the same indications as the reference medicine, namely the prevention of thromboembolic complications from atrial fibrillation (AF), venous thromboembolism (VTE) or pulmonary embolism (PE). PrSandoz® Edoxaban is available in 15 mg, 30 mg and 60 mg tablets and has a similar appearance to the reference medicine to facilitate patients’ transition. “We are proud to expand our generics portfolio with a launch that is expected to generate savings for governments, private insurers and patients. The launch of Edoxaban reflects our deep commitment to our Purpose of pioneering access for patients, as we provide more options for those suffering from heart conditions.” says Michel Robidoux, President and General Manager of Sandoz Canada Atrial fibrillation (AF) affects over half a million Canadians, who are at a three to five-fold increased risk of stroke compared to the general population , with an estimated financial burden of over $3.6 billion a year . As many AF patients are prescribed long-term anti-coagulants the launch of this more affordable, quality generic version is expected to ease some of the financial burden on patients and on the Canadian healthcare system. 1The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation Volume 36, Issue 12, p1847-1948, December 2020 2Heart and Stroke Foundation of Canada, Cost section, Connected by the numbers | Heart and Stroke Foundation ® Lixiana is a registered trademark of Daiichi Sankyo Company Limited. Disclaimer This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. About Sandoz Canada As a Canadian leader in off-patent medicines, Sandoz Canada has a product portfolio that includes over 700 generics and biosimilars spanning multiple therapeutic areas, such as anti-infective, cardiovascular, central nervous system, immunology and oncology. In 2024, 56 million Sandoz prescriptions were issued in Canada (source: IQVIA Compuscript TRx). Sandoz Canada employs 300 people across the country and at its head office in Boucherville, Quebec. It is a trusted partner for pharmacists, physicians and hospitals for quality medicine and outstanding customer service and is committed to ensuring a reliable supply. For more information about Sandoz Canada, visit www.sandoz.ca. About Sandoz AG Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: Pioneering access for patients. 20,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 900 million patients worldwide, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of more than 1,300 products addresses diseases from common colds to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. Sophie Levasseur Manager, Corporate Communications sophie-1.levasseur@sandoz.com +1 263 788-3835

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with the class of end payer plaintiffs for USD 275 millionProvision of USD 265 million taken to cover potential additional settlement costs with regard to the US generic drug industry antitrust litigationNo impact on current Sandoz full-year 2024 and mid-term guidance Basel, December 17, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced settlements with the US Department of Justice in 2020 and 2021 and with the direct purchaser plaintiffs’ class in February 2024, Sandoz has now also entered into a settlement agreement with the end payer plaintiffs’ class for a total of USD 275 million, which is expected to be paid before December 31, 2024. The company has also taken a provision of USD 265 million for the outstanding claims brought by opt-out plaintiffs and State Attorneys’ General. The settlement payment and the provision will be included in the company’s 2024 financial results. This does not affect current Sandoz full-year 2024 and mid-term guidance. End payer plaintiffs class settlement Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. – both indirect subsidiaries of Sandoz Group AG – have entered into a settlement agreement with the class of end payer plaintiffs in the multi-district litigation entitled In re Generic Pharmaceuticals Pricing Antitrust Litigation in the US District Court for the Eastern District of Pennsylvania. This agreement, which contains no admission of wrongdoing by Sandoz US, resolves all of the damages claims of the end payer class, which is comprised generally of certain consumers, insurers, health and welfare funds, employee benefit plans, and other entities that paid for and reimbursed the sales of drugs. Under the terms of the agreement, Sandoz US will pay USD 275 million in exchange for a full release of all claims asserted against it in the end payer class action by the settlement class members. This settlement underscores Sandoz commitment towards integrity and sound governance, and it is an encouraging step toward resolving allegations of legacy conduct. Beyond the payment, settlement terms include: A broad release of claims that covers alleged conduct between 2009 and 2019 as well as all medicines at issue in the end purchaser class claimsClass members have the right to opt out of the settlement, which could result in the settlement amount being reduced by up to USD 45 million The settlement is subject to Court approval, as is required for class settlements under US law. If the Court preliminarily approves the settlement, class members will be notified of the settlement and given an opportunity to opt out of the class, object to the settlement, and file a claim to receive a settlement payment. Remaining claims related to the US generic antitrust litigation The remaining claims are seeking damages for alleged anticompetitive conduct in the US market. These claims are brought by certain US States and Territories as well as the indirect reseller plaintiff class and individual plaintiffs in the multidistrict litigation. Sandoz US continues to defend itself vigorously in those cases, and has raised a number of defenses, including whether downstream purchasers were actually damaged due to the alleged conduct. Based on its current assessment of these remaining claims, Sandoz set up a provision of USD 265 million. As the litigation progresses, Sandoz will continue to assess the overall situation and may increase or decrease the provision as appropriate. Other generic antitrust litigation In addition to the US generic antitrust litigation, as previously disclosed, Sandoz Inc., Sandoz Canada Inc., and Fougera Pharmaceuticals Inc. have been named in a class action in Ontario, Canada alleging price fixing in the Canadian generic pharmaceutical market. The claims are being vigorously contested. DISCLAIMERThis Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. ABOUT SANDOZSandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion. CONTACTS Global Media Relations contactsInvestor Relations contactsGlobal.MediaRelations@sandoz.com Investor.Relations@sandoz.com Joerg E. Allgaeuer+49 171 838 4838Laurent de Weck+41 79 795 7364 Attachment Media release_US generic drug antitrust class action litigation.pdf